Evidence map›Paper›PMID 29611086›Full record

Trial reportClinical rheumatology2018

Resveratrol as an effective adjuvant therapy in the management of rheumatoid arthritis: a clinical study.

Hani M Khojah, Sameh Ahmed, Mahran S Abdel-Rahman, Eman H Elhakeim

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Clinical rheumatology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07089381 (Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.), which is not on this map. Cited by 75 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 7 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07089381 narecruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.

TypeinterventionalSponsorAin Shams UniversityRan2025 to 2026Enrolled118ConditionsRheumatic Arthritis, Rheumatoid Arthritis (RA) Prevention, Inflamation, AntioxidantArmsResveratrol 1 gm., Methotrexate
3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 7 syntheses or guidelines pooled it, 137 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Hani M KhojahDepartment of Clinical and Hospital Pharmacy, College of Pharmacy, Taibah University, Medina, Saudi Arabia. hkhojah@taibahu.edu.sa.
Sameh AhmedDepartment of Pharmacognosy and Pharmaceutical Chemistry, College of Pharmacy, Taibah University, Medina, Saudi Arabia.
Mahran S Abdel-RahmanDepartment of Pharmacology, Faculty of Medicine, Assiut University, Assiut, Egypt.
Eman H ElhakeimDepartment of Rheumatology & Rehabilitation, Faculty of Medicine, Assiut University, Assiut, Egypt.
Assiut University · EGTaibah University · SA

Funding

Taibah University 8014/437
6 · The paper itself

Abstract

Resveratrol (RSV), a naturally occurring polyphenol, has been found to have potent antioxidant, anti-inflammatory, and anticancer effects. Recently, RSV was reported as a new potential agent to suppress inflammation of collagen-induced arthritis in a mouse model. Nevertheless, the clinical benefits of RSV in the management of rheumatoid arthritis (RA) were not studied. This randomized controlled clinical trial aims to shed some light on the therapeutic benefits of RSV in the treatment of RA in patients with different stages of the disease activity. In this randomized controlled clinical trial, 100 RA patients (68 female, 32 male) were enrolled randomly and divided into two groups, each of 50 patients: an RSV-treated group that received a daily RSV capsule of 1 g with the conventional treatment for 3 months and a control group that just received the regular treatment. The clinical and biochemical markers of RA in both groups were assessed. It was found that the clinical markers (i.e., the 28-joint count for swelling and tenderness) and the disease activity score assessment for 28 joints were significantly lowered in the RSV-treated group. Moreover, serum levels of certain biochemical markers (i.e., C-reactive protein, erythrocyte sedimentation rate, undercarboxylated osteocalcin, matrix metalloproteinase-3, tumor necrosis factor alpha, and interleukin-6) were also significantly decreased in RSV-treated patients. The current study suggests the addition of RSV as an adjuvant to the conventional antirheumatic drugs.

Indexed as

AdultAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsArthritis, RheumatoidChemotherapy, AdjuvantEgyptFemaleHumansMaleMiddle AgedResveratrolSeverity of Illness IndexTreatment OutcomeTumor Necrosis Factor-alphaAnti-Inflammatory Agents, Non-SteroidalAntirheumatic AgentsResveratrolTumor Necrosis Factor-alphaDAS28-ESRResveratrolRheumatoid arthritisTNF-αucOC

Identifiers

PMID29611086
OpenAlexW2796035257

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.